Clinical trials: Residual Disease
Myeloma
Place of the Hevylite Test in the Evaluation of MRD in Myeloma
Study aiming at testing the positive predictive value of the Hevylite blood test in detecting minimal residual disease in myeloma compared to an invasive method requiring bone marrow sample by multi-parametric flow cytometry
- Trial name
- NCT03702088
- Where
- France
- Volunteers
- 124 people
- Sponsor
- University Hospital, Montpellier
Acute Myeloid Leukemia, Adult
Midostaurin in MRD (Minimal Residual Disease) Positive Acute Myeloid Leukemia After Allogeneic Stem Cell Transplantation
The MAURITIUS trial is a single-arm, multicenter phase II study of single treatment with midostaurin being applied to AML (acute myeloid leukemia) patients with activating FLT3 (FMS-like tyrosine kinase3) mutations and either…
- Trial name
- NCT03951961
- Testing
- Midostaurin
- Where
- 4 sites in Germany
- Volunteers
- 1 people
- Sponsor
- University of Jena
Major Depressive Disorder
Iloperidone Augmentation of SSRIs for Patients With Major Depressive Disorder With Residual Anger and Irritability
Iloperidone is an atypical antipsychotic drug, FDA-approved for the acute treatment of schizophrenia in adults in 2009 (Marino et al., 2010); moreover, some of its pharmacological features seem to be very promising in treating…
- Trial name
- NCT01464229
- Testing
- Iloperidone
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Maurizio Fava, MD
Participants With Underactive Bladder (UAB)
A Proof-Of-Concept (POC) Study of SFG-02 Transdermal Formulation in Participants With Underactive Bladder (UAB)
The objective of this POC (Phase 2a) study is to evaluate the effect on Bladder Voiding Efficiency (BVE) as well as safety of SFG-02 transdermal formulation in participants with UAB.
- Trial name
- NCT07906106
- Testing
- SFG-02
- Where
- 16 sites in Japan
- Volunteers
- 70 people
- Sponsor
- Juro Sciences Inc.
Juvenile Myelomonocytic Leukemia, Recurrent Acute Biphenotypic Leukemia
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
This phase I trial studies the side effects and best dose of CD4+ and CD8+ HA-1 T cell receptor (TCR) (HA-1 T TCR) T cells in treating patients with acute leukemia that persists, has come back (recurrent) or does not respond to…
- Conditions
- Juvenile Myelomonocytic Leukemia, Recurrent Acute Biphenotypic Leukemia, Recurrent Acute Undifferentiated Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia
- Trial name
- NCT03326921
- Testing
- CD8+ and CD4+ Donor Memory T-cells-expressing HA1-Specific TCR, Bone Marrow Aspiration, Biospecimen Collection
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Fred Hutchinson Cancer Center
Colonic Adenoma, Colon Polyp
Comparison of the Benefit of Chromoendoscopy in Addition to High Definition White Light and Narrow Band Imaging for the Prediction of Submucosal Invasive Cancer in Colonic Lesions
To compare the incremental benefit of chromoendoscopy in addition to high definition white light and narrow band imaging in predicting submucosal invasion within laterally spreading lesions in the colon and in determining the…
- Conditions
- Colonic Adenoma, Colon Polyp, Submucosal Invasive Colon Adenocarcinoma, Colorectal Cancer
- Trial name
- LANS (NCT03506321)
- Testing
- chromoendoscopy, high definition white light and narrow band imaging
- Where
- Australia
- Volunteers
- 400 people
- Sponsor
- Western Sydney Local Health District
B-cell Precursor Acute Lymphoblastic Leukemia (ALL)
BEBT-908 in MEF2D-Rearranged Relapsed/Refractory or MRD-Positive B-Cell Precursor Acute Lymphoblastic Leukemia
This is a single-center, open-label, exploratory study evaluating ifupinostat hydrochloride (BEBT-908) in patients with B-cell precursor acute lymphoblastic leukemia (BCP-ALL) with MEF2D rearrangement.
- Trial name
- NCT07854652
- Testing
- Ifupinostat Hydrochloride
- Where
- China
- Volunteers
- 15 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Lymphoma
Monoclonal Antibodies in Detecting Residual Disease in Patients Who Have Been Treated for Non-Hodgkin's Lymphoma
RATIONALE: Diagnostic imaging procedures, such as radiolabeled monoclonal antibodies, may improve the ability to detect the residual disease in patients who have been treated for non-Hodgkin's lymphoma.
- Trial name
- NCT00003338
- Testing
- immunoscintigraphy, technetium Tc 99m epratuzumab
- Where
- 8 sites in United States, Austria and 3 more
- Volunteers
- 60 people
- Sponsor
- Gilead Sciences
Non-Small Cell Lung Cancer
Minimal Residual Disease Guiding Adjuvant Therapy in Stage I NSCLC
This investigator-initiated study aims to evaluate the effectiveness of minimal residual disease (MRD) as a biomarker for guiding adjuvant therapy decisions in patients with Stage I non-small-cell lung cancer (NSCLC).
- Trial name
- MOTION-NSCLC (NCT06709274)
- Testing
- Osimertinib, Alectinib, TORIPALIMAB INJECTION (JS001 ) combine with chemotherapy
- Where
- 15 sites in China
- Volunteers
- 342 people
- Sponsor
- Guangdong Association of Clinical Trials
Breast Cancer
Comparison of MRI and CEDM to Evaluate Treatment Response Before Surgery
The purpose of this study is to compare the diagnostic accuracy of breast magnetic resonance imaging (MRI) and contrast enhanced digital mammography (CEDM) in assessing the residual disease extent in patients who have completed…
- Trial name
- NCT03070340
- Testing
- Breast Magnetic Resonance Imaging (MRI), Contrast Enhanced Mammography (CEDM)
- Where
- 5 sites in United States
- Volunteers
- 125 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Diffuse Large B-Cell Lymphoma
Chidamide Maintenance for MRD-Positive Double-Expressor DLBCL in First Complete Remission
This is a prospective, multicenter, single-arm, open-label phase 2 study designed to evaluate the efficacy and safety of chidamide maintenance in adults with newly diagnosed double-expressor diffuse large B-cell lymphoma (DLBCL)…
- Trial name
- DEL-MRD-CHID (NCT07507318)
- Testing
- Chidamide
- Where
- China
- Volunteers
- 69 people
- Sponsor
- Rong Tao
Acute Lymphoblastic Leukemia, Pediatric
Minimal Residual Disease Quantification by Next-generation Sequencing in Pediatric B-ALL Children Patients Treated With Blinatumomab Consolidation
A retrospective analysis to investigate pediatric B-cell acute lymphoblastic leukemia patients who were treated with blinatumomab for consolidation, and who were detected as minimal residual disease (MRD) positive by next…
- Trial name
- NCT05837689
- Testing
- Blinatumomab
- Volunteers
- 20 people
- Sponsor
- Xiaojun Xu
Carotid Arteriosclerosis, Carotid Stenosis
Residual Stenosis and Restenosis Following Carotid Endarterectomy With Primary Closure, A Prospective Tracking Study
This prospective, multicenter observational study aims to evaluate the incidence, timing, and characteristics of residual and recurrent (restenosis) carotid artery stenosis following carotid endarterectomy (CEA) with primary…
- Conditions
- Carotid Arteriosclerosis, Carotid Stenosis, Brain Stroke
- Trial name
- RECEPT (NCT07057297)
- Where
- Czechia
- Volunteers
- 300 people
- Sponsor
- Charles University, Czech Republic
Obstructive Sleep Apnea, Hypopnea
Armodafinil (CEP-10953) in Treatment of Excessive Sleepiness Associated With Obstructive Sleep Apnea/Hypopnea Syndrome(OSAHS)
The primary objective of this study is to determine whether treatment with Armodafinil (CEP-10953) is more effective than placebo treatment for patients with excessive sleepiness associated with obstructive sleep apnea/hypopnea…
- Trial name
- NCT00078325
- Testing
- Armodafinil 250 mg/day, Armodafinil 150 mg/day
- Volunteers
- 395 people
- Sponsor
- Cephalon
Multiple Myeloma Refractory, Multiple Myeloma in Relapse
Elranatamab With Mezigdomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma
The goal of this clinical trial is to learn if the drug combination Elranatamab plus Mezigdomide plus Dexametahsone works to cure patients with relapsed/refractory multiple myeloma.
- Trial name
- GEM-MeziDEL (NCT07901868)
- Testing
- Dexamethasone, Mezigdomide, Elranatamab
- Where
- 20 sites in Spain
- Volunteers
- 60 people
- Sponsor
- PETHEMA Foundation
Muscle Invasive Bladder Urothelial Carcinoma, Muscle-Invasive Bladder Carcinoma
Surveillance of the Genetic Signature in Circulating Tumor DNA for Guiding Adjuvant Chemotherapy in Urothelial Carcinoma
Urothelial carcinomas are one of the most commonly diagnosed cancers worldwide. Postoperative patients carry a poor prognosis with an estimated five-year disease-specific survival rate of 50%.
- Trial name
- NCT06257017
- Testing
- gemcitabine, Cisplatin
- Where
- Hong Kong
- Volunteers
- 15 people
- Sponsor
- Yung NA
Glaucoma; Drugs
Efficacy of Tafluprost as an Adjunct to Medical Therapy for Residual Glaucoma After Trabeculectomy
A 6-month, parallel-group study of the safety and efficacy of tafluprostin for Chinese patients with posttrabeculectomy residual primary angle-closure glaucoma or posttrabeculectomy residual primary open angle glaucoma.
- Trial name
- NCT03595865
- Testing
- tafluprostin
- Volunteers
- 60 people
- Sponsor
- wangdabo
Periodontal Pocket, Periodontitis
"Re-instrumentation vs Flap Surgery"
There are no studies comparing reinstrumentation and flap surgery for the treatment of residual periodontal pockets. The aim of this RCT is to compare the re-instrumentation vs the flap surgery in terms of PD reduction, CAL gain…
- Trial name
- NCT05460988
- Testing
- Flap surgery, Non surgical re-instrumentation
- Where
- Italy
- Volunteers
- 46 people
- Sponsor
- University of Florence
Fasting, Gastric Stasis
Residual Gastric Volume After the Ingestion of Supplements Containing Carbohydrates and Whey Protein
Oral supplements (OS) containing carbohydrates are being used 2h before anesthesia. The addition of a nitrogen source would improve these drinks designed for the abbreviation of preoperative fasting.
- Conditions
- Fasting, Gastric Stasis, Perioperative Complication, Safety Issues
- Trial name
- NCT05573854
- Testing
- Gastric emptying after an oral supplement containing carbohydrates and whey protein, Overnight Fast
- Where
- Brazil
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Federal University of Mato Grosso
Glioma
Tessa Jowell BRAIN MATRIX - Platform Study
The main aim of the Tessa Jowell BRAIN MATRIX - Platform Study is to more precisely determine the exact type of tumour patients have by developing the essential infrastructure to provide rapid and accurate molecular diagnosis.
- Trial name
- BRAIN MATRIX (NCT04274283)
- Testing
- Matched Tumour and Blood Sample - Research Pathway, Matched Tumour and Blood Sample - NHS GMS pathway
- Where
- 14 sites in United Kingdom
- Volunteers
- 1,000 people
- Sponsor
- University of Birmingham
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.